lyriccal12

lyriccal12

This Company engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA . CRSP and Vertex creates new possibilities in medicine to cure diseases and improve people's lives. We work with leading researchers,...

lyriccal12

Engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term...

lyriccal12

A company that designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. anticipates two regulatory approvals for berotralstat in 2020, Even more impressive, that BCRX will likely get a significant near-term boost from the success of...